Outcomes reflect key findings: limited efficacy for beta-blockers/ACEi [32], modest benefits for spironolactone (TOPCAT, 2014) [10], neutral results for sacubitril/valsartan (PARAGON-HF, 2019) [9], reduced heart failure (HF) events for SGLT2i (DELIVER/EMPEROR-Preserved, 2021-2022) [11,12], and improved quality of life (QoL), weight loss, C-reactive protein (CRP) reduction, and 6-minute walk test (6MWT) distance with semaglutide (STEP HFpEF, 2023) [16]. The gene discussed is CRP; the disease is hydrops fetalis.